PSA screening cut prostate cancer deaths by 20 percent over 16 years
The largest randomised trial of prostate cancer screening followed men for 16 years. Screening reduced deaths, at the cost of overdiagnosis.
Prostate cancer is the most commonly diagnosed cancer in men in many countries. Whether to screen for it with a PSA blood test has been debated for decades. The European Randomized Study of Screening for Prostate Cancer (ERSPC) is the largest trial to answer it.
Jonas Hugosson, Monique Roobol and colleagues published the 16-year follow-up in European Urology in 2019. Men aged 55 to 69 in eight European countries were randomly invited to regular PSA screening or not invited.
What they found
- After 16 years, screening reduced prostate cancer deaths by 20 percent.
- About 570 men needed to be invited to screening to prevent one prostate cancer death.
- About 18 additional men needed to be diagnosed with prostate cancer to prevent one death, a measure of overdiagnosis.
- The benefit grew with longer follow-up.
What it means
PSA screening saves lives, but it also finds many slow-growing cancers that would never have caused harm. Treating those can lead to incontinence and erectile problems. Modern practice reduces that harm: MRI before biopsy, and active surveillance rather than immediate surgery for low-risk cancers.
How to apply it
- From about age 50, or 45 if you are at higher risk, discuss PSA testing with your doctor.
- Higher risk includes Black men and men with a father or brother diagnosed with prostate cancer.
- A single raised PSA is not a diagnosis. Infection, an enlarged prostate and recent cycling or ejaculation can raise it.
- Ask whether an MRI is available before any biopsy.
- If a low-risk cancer is found, ask about active surveillance.
A note on the evidence
The results varied between countries, partly because men in the control groups also had PSA tests outside the trial. The trial began before MRI was routine, so screening today may have a better balance of benefit and harm.
Sources
- Hugosson J et al. A 16-yr follow-up of the European Randomized study of Screening for Prostate Cancer. European Urology, 2019. doi:10.1016/j.eururo.2019.02.009




